A groundbreaking blood test developed by US researchers offers hope for early preeclampsia detection during pregnancy. The innovative test uses RNA signatures to predict the risk of this serious pregnancy complication with remarkable 91% accuracy. Designed to identify potential issues months before symptoms emerge, the test is particularly valuable for women over 35 and those with low-risk pregnancies. This research, published in Nature Communications, represents a significant advancement in maternal healthcare and potential preventive strategies.
April 09, 2025
US researchers develop simple blood test to predict preeclampsia during pregnancy
A team of US researchers
has developed a simple blood test that can predict preeclampsia -- a serious
pregnancy complication characterised by high blood pressure.
Key Points
1 Revolutionary blood test identifies preeclampsia risk months before
symptoms
2 Effective for women over 35 with low-risk pregnancies
3 99.7% accuracy in predicting preterm complications
4 Uses advanced RNA signature screening
Preeclampsia, which occurs usually after 20 weeks of gestation, is a
leading cause of maternal morbidity and mortality as well as preterm birth.
Despite the use of general
maternal characteristics to identify pregnant women at increased risk for
preeclampsia, rates of the disease have nearly doubled in the last decade.
The new blood test, which
uses RNA signatures, showed that it can identify the risk of preeclampsia in 91
per cent of pregnancies.
"By the time a
patient is symptomatic, it's a race against the clock to try to get the baby to
term and not risk the mother's health," said Dr. Kara Rood, a
maternal-foetal medicine physician, one of the principal investigators of the
study at The Ohio State University Wexner Medical Centre.
The new test could
identify the risk, months ahead of symptoms, in women aged over 35 and without
pre-existing high-risk conditions.
It could predict
preeclampsia early, at 17.5 to 22 weeks gestational age, in pregnancies without
any pre-existing high-risk conditions.
Those with a low-risk
result have a 99.7 per cent probability of not developing preterm preeclampsia.
"Current guidelines
are not helping us identify which patients are truly at high risk and we need
better tools. This preeclampsia risk prediction test can now improve risk
assessment, helping women and their care teams be informed and take actions
with the potential to delay the onset of or prevent the disease," Rood
added.
The study, published in
the journal Nature Communications, demonstrates that relying on molecular
signals from the underlying biology is far more effective in determining whether
the risk of preeclampsia is high or low.
To develop the blood test,
the team used data from more than 9,000 pregnancies within the multi-centre
prospective study to discover and validate RNA signatures capable of
distinguishing between severe and mild hypertensive disorders of pregnancy,
including preeclampsia, months before symptoms occur.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment